Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of EGFR Mutations in Non-small Cell Lung Carcinoma and the Correlation with Clinical Responses to EGFR Tyrosine Kinase Inhibitor Treatment
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hyun Ju | - |
dc.contributor.author | Xu, Xianhua | - |
dc.contributor.author | Kim, Hyojin | - |
dc.contributor.author | Jin, Yan | - |
dc.contributor.author | Sun, Pingli | - |
dc.contributor.author | Kim, Ji Eun | - |
dc.contributor.author | Chung, Jin-Haeng | - |
dc.date.accessioned | 2021-08-12T01:25:34Z | - |
dc.date.available | 2021-08-12T01:25:34Z | - |
dc.date.issued | 2013-02 | - |
dc.identifier.issn | 1738-1843 | - |
dc.identifier.issn | 2092-8920 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/13965 | - |
dc.description.abstract | Background: The aims of this study were to evaluate the abilities of direct sequencing (DS), peptide nucleic acid (PNA) clamping, and pyrosequencing methods to detect epidermal growth factor receptor (EGFR) mutations in formalin-fixed paraffin-embedded (FFPE) non-small cell lung carcinoma (NSCLC) samples and to correlate EGFR mutational status as determined by each method with the clinical response to EGFR tyrosine kinase inhibitors (TKIs). Methods: Sixty-one NSCLC patients treated with EGFR TKIs were identified to investigate somatic mutations in the EGFR gene (exons 18-21). Results: Mutations in the EGFR gene were detected in 38 of the 61 patients (62%) by DS, 35 (57%) by PNA clamping and 37 (61%) by pyrosequencing. A total of 44 mutations (72%) were found by at least one of the three methods, and the concordances among the results were relatively high (82-85%; kappa coefficient, 0.713 to 0.736). There were 15 discordant cases (25%) among the three different methods. Conclusions: All three EGFR mutation tests had good concordance rates (over 82%) for FFPE samples. These results suggest that if the DNA quality and enrichment of tumor cells are assured, then DS, PNA clamping, and pyrosequencing are appropriate methods for the detection of EGFR mutations. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Korean Society of Pathologists | - |
dc.title | Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of EGFR Mutations in Non-small Cell Lung Carcinoma and the Correlation with Clinical Responses to EGFR Tyrosine Kinase Inhibitor Treatment | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.4132/KoreanJPathol.2013.47.1.52 | - |
dc.identifier.scopusid | 2-s2.0-84874972652 | - |
dc.identifier.wosid | 000315974600008 | - |
dc.identifier.bibliographicCitation | Korean Journal of Pathology, v.47, no.1, pp 52 - 60 | - |
dc.citation.title | Korean Journal of Pathology | - |
dc.citation.volume | 47 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 52 | - |
dc.citation.endPage | 60 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pathology | - |
dc.relation.journalWebOfScienceCategory | Pathology | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | GEFITINIB | - |
dc.subject.keywordAuthor | Lung neoplasms | - |
dc.subject.keywordAuthor | Receptor, epidermal growth factor | - |
dc.subject.keywordAuthor | Mutation | - |
dc.subject.keywordAuthor | Sequencing analysis, DNA | - |
dc.subject.keywordAuthor | Peptide nucleic acids | - |
dc.subject.keywordAuthor | Pyrosequencing | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.